Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEM-PRO: neoadjuvant pembrolizumab before radical prostatectomy in high-risk prostate cancer
2019-004782-40Phase 2Active
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in prostate cancer (PCa), sponsored by IRCCS Ospedale San Raffaele. Primary endpoint: Rate of node-negative disease at radical prostatectomy. Started Jan 2021; status: active.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2019-004782-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004782-40.